ArticleBMC geriatrics2026
Theoretical impact of a mobile team dedicated to patients with Alzheimer's disease and related dementias on medication exposure in community-dwelling older patients (MEMORIAS study).
Article in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlzheimer's disease and related dementias (ADRD) are frequently associated with behavioral and psychological symptoms of dementia (BPSD), which complicate care, increase medication exposure and cognitive iatrogenic risk. The mobile team for ADRD (MTAD) provides therapeutic recommendations for acute cases following home interventions.
objectivesThis study evaluated the theoretical impact of MTAD medication recommendations on medication exposure in community-dwelling older patients with neurocognitive disorders (NCD) and BPSD.
methodsThis retrospective single-center study included older patients with NCDs visited by MTAD. Medication exposure was evaluated theoretically, assuming full implementation of MTAD medication recommendations, based on medication number, prevalence of potentially inappropriate medications (PIMs) identified using the EU(7)-PIM list, and sedative/anticholinergic burden quantified by the Drug Burden Index (DBI). MTAD medication recommendations were classified.
resultsAmong 246 patients (mean age 83.9 years), MTAD recommendations would result in a significant reduction in PIMs per patient (0.91 versus 0.79, p < 0.001), with a significant increase in the overall and sedative DBI (0.55 versus 0.74, p < 0.001; 0.46 versus 0.65, p < 0.001, respectively), and number of prescribed medications (6.5 versus 6.9, p < 0.001), without change in the anticholinergic DBI (0.25 versus 0.26, p = 0.206). A total of 337 recommendations were issued, mainly additions (51%) and discontinuations (23%), primarily targeting psychotropics.
conclusionsThe theoretical implementation of MTAD recommendations for older patients with BPSD could reduce exposure to PIMs and may lead to an increased use of sedatives. However, further efforts are needed to optimize somatic treatments and minimize iatrogenic risks through comprehensive medication reviews.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.